Ashurst acted as the U.S. counsel to Shanghai Voicecomm Information Technology, while O’Melveny represented the underwriters on the offering. Shanghai Voicecomm Information Technology Co., Ltd. (2495.HK)...
You must be a Standard 1 Year member to access this content.
O’Melveny represented FOLANGSI CO., LTD in the transaction. FOLANGSI CO., LTD (2499.HK) (“FOLANGSI”) announced its approximately HK$155 million initial public offering and listing of H shares...
You must be a Standard 1 Year member to access this content.
O’Melveny advised Beauty Farm. Clifford Chance has advised the joint sponsors. Shearman & Sterling advised Beijing Xinyu Meiye Holdings Limited as a selling shareholder. Beauty Farm...
You must be a Standard 1 Year member to access this content.
Cooley advised the joint sponsors and underwriters on the deal while O’Melveny represented Cryofocus Medtech (Shanghai) Co., Ltd. Cryofocus Medtech announced its HK$210 million ($27 million) initial...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised the underwriters on the deal while O’Melveny represented OrbusNeich Medical Group. OrbusNeich Medical Group Holdings Limited (6929.HK) announced its approximate US$61.6 million (approximately HK$481...
You must be a Standard 1 Year member to access this content.
O’Melveny represented Jenscare Scientific Co., Ltd on the deal. Herbert Smith Freehills advised China International Capital Corporation and Citigroup. Jenscare Scientific Co., Ltd. (9877.HK) announced its...
You must be a Standard 1 Year member to access this content.
O’Melveny represented RemeGen Co. on the deal. RemeGen Co., Ltd. (“RemeGen”) (9995.HK; 688331.SH) announced its A-share listing on the Sci-Tech Innovation Board of the Shanghai Stock...
You must be a Standard 1 Year member to access this content.
Herbert Smith Freehills has advised Huatai Financial Holdings (Hong Kong) Limited. O’Melveny & Myers represented Bio-heart on the deal. Huatai Financial Holdings (Hong Kong) Limited acted...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers and Maples and Calder advised Brii Biosciences Limited on the deal. Herbert Smith Freehills has advised Morgan Stanley and UBS. Brii Biosciences Limited...
You must be a Standard 1 Year member to access this content.
O’Melveny & Myers and Cooley LLP advised Keymed Biosciences Inc. on the deal, while Kirkland & Ellis advised the joint sponsors and underwriters. Keymed Biosciences Inc....
You must be a Standard 1 Year member to access this content.
Herbert Smith Freehills has advised Morgan Stanley Asia Limited and Huatai Financial Holdings as joint sponsors. O’Melveny & Myers LLP and and Jingtian & Gongcheng advised...
You must be a Standard 1 Year member to access this content.
